Cargando…

CDK4/6 inhibition synergizes with inhibition of P21-Activated Kinases (PAKs) in lung cancer cell lines

Theoretically, small molecule CDK4/6 inhibitors (CDK4/6is) represent a logical therapeutic option in non-small cell lung cancers since most of these malignancies have wildtype RB, the key target of CDKs and master regulator of the cell cycle. Unfortunately, CDK4/6is are found to have limited clinica...

Descripción completa

Detalles Bibliográficos
Autores principales: Wright, Gabriela M., Gimbrone, Nick T., Sarcar, Bhaswati, Percy, Trent R., Gordián, Edna R., Kinose, Fumi, Sumi, Natália J., Rix, Uwe, Cress, W. Douglas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8211232/
https://www.ncbi.nlm.nih.gov/pubmed/34138895
http://dx.doi.org/10.1371/journal.pone.0252927
_version_ 1783709439639945216
author Wright, Gabriela M.
Gimbrone, Nick T.
Sarcar, Bhaswati
Percy, Trent R.
Gordián, Edna R.
Kinose, Fumi
Sumi, Natália J.
Rix, Uwe
Cress, W. Douglas
author_facet Wright, Gabriela M.
Gimbrone, Nick T.
Sarcar, Bhaswati
Percy, Trent R.
Gordián, Edna R.
Kinose, Fumi
Sumi, Natália J.
Rix, Uwe
Cress, W. Douglas
author_sort Wright, Gabriela M.
collection PubMed
description Theoretically, small molecule CDK4/6 inhibitors (CDK4/6is) represent a logical therapeutic option in non-small cell lung cancers since most of these malignancies have wildtype RB, the key target of CDKs and master regulator of the cell cycle. Unfortunately, CDK4/6is are found to have limited clinical activity as single agents in non-small cell lung cancer. To address this problem and to identify effective CDK4/6i combinations, we screened a library of targeted agents for efficacy in four non-small cell lung cancer lines treated with CDK4/6 inhibitors Palbociclib or Abemaciclib. The pan-PAK (p21-activated kinase) inhibitor PF03758309 emerged as a promising candidate with viability ratios indicating synergy in all 4 cell lines and for both CDK4/6is. It is noteworthy that the PAKs are downstream effectors of small GTPases Rac1 and Cdc42 and are overexpressed in a wide variety of cancers. Individually the compounds primarily induced cell cycle arrest; however, the synergistic combination induced apoptosis, accounting for the synergy. Surprisingly, while the pan-PAK inhibitor PF03758309 synergizes with CDK4/6is, no synergy occurs with group I PAK inhibitors FRAX486 or FRAX597. Cell lines treated only with Ribociclib, FRAX486 or FRAX597 underwent G1/G0 arrest, whereas combination treatment with these compounds predominantly resulted in autophagy. Combining high concentrations of FRAX486, which weakly inhibits PAK4, and Ribociclib, mimics the autophagy and apoptotic effect of PF03758309 combined with Ribociclib. FRAX597, a PAKi that does not inhibit PAK4 did not reduce autophagy in combination with Ribociclib. Our results suggest that a unique combination of PAKs plays a crucial role in the synergy of PAK inhibitors with CDK4/6i. Targeting this unique PAK combination, could greatly improve the efficacy of CDK4/6i and broaden the spectrum of cancer treatment.
format Online
Article
Text
id pubmed-8211232
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-82112322021-06-29 CDK4/6 inhibition synergizes with inhibition of P21-Activated Kinases (PAKs) in lung cancer cell lines Wright, Gabriela M. Gimbrone, Nick T. Sarcar, Bhaswati Percy, Trent R. Gordián, Edna R. Kinose, Fumi Sumi, Natália J. Rix, Uwe Cress, W. Douglas PLoS One Research Article Theoretically, small molecule CDK4/6 inhibitors (CDK4/6is) represent a logical therapeutic option in non-small cell lung cancers since most of these malignancies have wildtype RB, the key target of CDKs and master regulator of the cell cycle. Unfortunately, CDK4/6is are found to have limited clinical activity as single agents in non-small cell lung cancer. To address this problem and to identify effective CDK4/6i combinations, we screened a library of targeted agents for efficacy in four non-small cell lung cancer lines treated with CDK4/6 inhibitors Palbociclib or Abemaciclib. The pan-PAK (p21-activated kinase) inhibitor PF03758309 emerged as a promising candidate with viability ratios indicating synergy in all 4 cell lines and for both CDK4/6is. It is noteworthy that the PAKs are downstream effectors of small GTPases Rac1 and Cdc42 and are overexpressed in a wide variety of cancers. Individually the compounds primarily induced cell cycle arrest; however, the synergistic combination induced apoptosis, accounting for the synergy. Surprisingly, while the pan-PAK inhibitor PF03758309 synergizes with CDK4/6is, no synergy occurs with group I PAK inhibitors FRAX486 or FRAX597. Cell lines treated only with Ribociclib, FRAX486 or FRAX597 underwent G1/G0 arrest, whereas combination treatment with these compounds predominantly resulted in autophagy. Combining high concentrations of FRAX486, which weakly inhibits PAK4, and Ribociclib, mimics the autophagy and apoptotic effect of PF03758309 combined with Ribociclib. FRAX597, a PAKi that does not inhibit PAK4 did not reduce autophagy in combination with Ribociclib. Our results suggest that a unique combination of PAKs plays a crucial role in the synergy of PAK inhibitors with CDK4/6i. Targeting this unique PAK combination, could greatly improve the efficacy of CDK4/6i and broaden the spectrum of cancer treatment. Public Library of Science 2021-06-17 /pmc/articles/PMC8211232/ /pubmed/34138895 http://dx.doi.org/10.1371/journal.pone.0252927 Text en © 2021 Wright et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Wright, Gabriela M.
Gimbrone, Nick T.
Sarcar, Bhaswati
Percy, Trent R.
Gordián, Edna R.
Kinose, Fumi
Sumi, Natália J.
Rix, Uwe
Cress, W. Douglas
CDK4/6 inhibition synergizes with inhibition of P21-Activated Kinases (PAKs) in lung cancer cell lines
title CDK4/6 inhibition synergizes with inhibition of P21-Activated Kinases (PAKs) in lung cancer cell lines
title_full CDK4/6 inhibition synergizes with inhibition of P21-Activated Kinases (PAKs) in lung cancer cell lines
title_fullStr CDK4/6 inhibition synergizes with inhibition of P21-Activated Kinases (PAKs) in lung cancer cell lines
title_full_unstemmed CDK4/6 inhibition synergizes with inhibition of P21-Activated Kinases (PAKs) in lung cancer cell lines
title_short CDK4/6 inhibition synergizes with inhibition of P21-Activated Kinases (PAKs) in lung cancer cell lines
title_sort cdk4/6 inhibition synergizes with inhibition of p21-activated kinases (paks) in lung cancer cell lines
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8211232/
https://www.ncbi.nlm.nih.gov/pubmed/34138895
http://dx.doi.org/10.1371/journal.pone.0252927
work_keys_str_mv AT wrightgabrielam cdk46inhibitionsynergizeswithinhibitionofp21activatedkinasespaksinlungcancercelllines
AT gimbronenickt cdk46inhibitionsynergizeswithinhibitionofp21activatedkinasespaksinlungcancercelllines
AT sarcarbhaswati cdk46inhibitionsynergizeswithinhibitionofp21activatedkinasespaksinlungcancercelllines
AT percytrentr cdk46inhibitionsynergizeswithinhibitionofp21activatedkinasespaksinlungcancercelllines
AT gordianednar cdk46inhibitionsynergizeswithinhibitionofp21activatedkinasespaksinlungcancercelllines
AT kinosefumi cdk46inhibitionsynergizeswithinhibitionofp21activatedkinasespaksinlungcancercelllines
AT suminataliaj cdk46inhibitionsynergizeswithinhibitionofp21activatedkinasespaksinlungcancercelllines
AT rixuwe cdk46inhibitionsynergizeswithinhibitionofp21activatedkinasespaksinlungcancercelllines
AT cresswdouglas cdk46inhibitionsynergizeswithinhibitionofp21activatedkinasespaksinlungcancercelllines